LUND, Sweden, Jan. 30, 2015 (GLOBE NEWSWIRE) -- The number of shares and votes in Active Biotech has changed as a result of the rights issue that was made during the end of 2014.
Today, the last trading day of the month, there are in total 89,908,298 shares and votes in Active Biotech.
For further information, please contact:
Hans Kolam, CFO
Tel: +46 (0)46 19 20 44
Active Biotech AB (publ) (Nasdaq Stockholm: ACTI) is a biotechnology company with focus on neurodegenerative diseases and cancer. Projects in pivotal phase are laquinimod, an orally administered small molecule with unique immunomodulatory properties for the treatment of multiple sclerosis, and tasquinimod, an oral immunomodulatory, anti-metastatic substance for the treatment of prostate cancer. The objective of the preclinical ISI project is to produce new, patentable chemical compounds for treatment of diseases in the company's focus areas. Please visit www.activebiotech.com for more information.
Active Biotech is required to publish the information contained in this press release in accordance with the Swedish Securities Market Act. This information was provided to the media for publication at 8:30 am CET on January 30, 2015.
Number of shares and votes in Active Biotech http://hugin.info/1002/R/1890086/669119.pdf
Source: Active Biotech